High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Authors: Preetesh Jain, Martin Dreyling, John F. Seymour, Michael Wang
Journal: Journal of Clinical Oncology (2020)

Article Tools REVIEW ARTICLES Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.02287 Journal of Clinical Oncology - published online before print October 19, 2020 PMID: 33074750 High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management Preetesh Jain , MBBS, MD, DM, PhD1xPreetesh JainSearch for articles by this author; Martin Dreyling, MD, PhD2xMartin DreylingSearch for articles by this author; John F. Seymour , MBBS, PhD3xJohn F. SeymourSearch for articles by this author; and Michael Wang, MD1xMichael WangSearch for articles by this author Show More 1Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX2Medizinische Klinik III, Ludwig Maximilian University Klinikum München, München, Germany3Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia https://doi.org/10.1200/JCO.20.02287 First Page Full Text PDF Figures and Tables © 2020 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Preetesh Jain, Michael WangCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTHigh-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and ManagementThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Martin DreylingConsulting or Advisory Role: Acerta Pharma/AstraZeneca, Bayer/Vital, Celgene/Jazz, Gilead Sciences, Janssen-Cilag, Novartis, Roche, BeigeneSpeakers' Bureau: Bayer Health, Celgene, Gilead Sciences, Janssen-Cilag, Roche Pharma AGResearch Funding: Celgene (Inst), Janssen-Cilag (Inst), Roche Pharma AG (Inst), AbbVie (Inst)Travel, Accommodations, Expenses: Celgene, Janssen-Cilag, Roche Pharma AGJohn F. SeymourHonoraria: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, TakedaConsulting or Advisory Role: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, MEI Pharma, MorphoSysSpeakers' Bureau: AbbVie, RocheResearch Funding: AbbVie, Celgene, Janssen, RocheExpert Testimony: RocheTravel, Accommodations, Expenses: AbbVie, RocheMichael WangStock and Other Ownership Interests: MoreHealthHonoraria: Janssen Research & Development, DAVAOncology, OMI, PeerView Institute for Medical Education (PVI), OBR Oncology, Onclive, Pharmacyclics, AstraZeneca, Targeted OncologyConsulting or Advisory Role: AstraZeneca, Janssen Research & Development, Celgene, MOREhealth, Juno Therapeutics, BioInvent International, Pharmacyclics/Janssen, Pulse Biosciences, AxImmune, Kite Pharma, Guidepoint Global, Loxo, InnoCare, Oncternal TherapeuticsResearch Funding: AstraZeneca, Janssen Research & Development, Pharmacyclics, Kite Pharma, Juno Therapeutics, BeiGene, Acerta Pharma, Oncternal Therapeutics, BioInvent International, Loxo, VelosBio, Celgene, Verastem, InnoCare, Molecular Templates, Eli LillyTravel, Accommodations, Expenses: Janssen Research & Development, AstraZeneca, Celgene, DAVAOncology, OMINo other potential conflicts of interest were reported.